Gastrointestinal Dysfunction in Parkinson's Disease: Current and Potential Therapeutics

Area of Science:

• Gastroenterology
• Neurology
• Microbiology

Background:

• Gastrointestinal (GI) dysfunctions, including dysphagia, gastroparesis, and constipation, are highly prevalent non-motor symptoms in Parkinson's disease (PD).
• These GI symptoms significantly reduce patient quality of life and complicate disease management.
• Current treatments for PD-related GI issues, like dietary changes and laxatives, are often ineffective, and approved medications show limited efficacy.

Purpose of the Study:

• To review common GI symptoms in PD and evaluate current treatment limitations.
• To explore novel therapeutic targets within the GI tract for managing PD-related symptoms.
• To highlight the potential of targeting the intestinal barrier, enteric nervous system (ENS), and gut microbiome.

Main Methods:

• Literature review of PD-related GI dysfunction.
• Analysis of current treatment strategies and their efficacy.
• Exploration of emerging therapeutic avenues and potential drug repurposing.

Main Results:

• PD-related GI dysfunctions are widespread but poorly understood at the cellular and tissue level in the enteric nervous system (ENS).
• Existing treatments for constipation and other GI issues in PD patients have demonstrated limited success.
• Novel therapeutic strategies focusing on the intestinal barrier, ENS, and gut microbiome are emerging.

Conclusions:

• Effective management of PD-related GI symptoms requires novel therapeutic approaches beyond conventional treatments.
• Targeting the intestinal barrier, ENS, and gut microbiome holds significant promise for alleviating GI dysfunction in Parkinson's disease.
• Further research into these areas could lead to improved clinical outcomes and quality of life for individuals with PD.